REG - Fusion Antibodies - Grant of U.S. Patent for OptiMAL

Fusion AntibodiesAnnouncement

05/08/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250805:nRSE0032Ua&default-theme=true

RNS Number : 0032U  Fusion Antibodies PLC  05 August 2025

5 August 2025

Fusion Antibodies plc

("Fusion" or the "Company")

 

Grant of U.S. Patent for OptiMAL®

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, is pleased to announce that the Company's patent application
no. 17/287,441 (the "Patent") has been granted by the United States Patent and
Trademark Office (the "U.S. Patent Office"). The grant of the Patent follows
the receipt of a notice of allowance in respect of the Patent from the U.S.
Patent Office, details of which were announced by the Company on 22 May 2025.

 

To view the supporting video by CEO Adrian Kinkaid and ask questions, please
go to the Fusion investor
hub: https://investorhub.fusionantibodies.com/link/8r6bdr
(https://urldefense.proofpoint.com/v2/url?u=https-3A__investorhub.fusionantibodies.com_link_8r6bdr&d=DwMFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=cCRJXtNlMluwccC8qKQfi6R1jPfdVSHZgF4lLESCxuk&m=RbxMw0dY1T68JeVLxeaOZCfJ-Q7GCoMRriO67uu9We5wMk0MNurfF89gZDjWXNgI&s=1P8moLVp11CEvQrmPBnOoolm7OxlLUZpvnJ2drVdJwU&e=)
 

 

The Patent entitled "Antibody Library and Method", concerns the library of
antibodies that is currently screened within Fusion's OptiMAL® platform, as
well as the method for the design of additional libraries. This is key to
Fusion's offering to provide "Opti" designed libraries for a range of
applications including Antibody Discovery, Affinity Maturation, and Sequence
Optimisation.

 

The Company is also progressing patent applications in respect of the
OptiMAL® Library in several other territories worldwide including Europe,
China and Japan.

 

Having secured the US patent, the Company is now targeting a scientific
presentation at the Antibody Engineering and Therapeutics conference in San
Diego in December 2025 and working toward a commercial launch of OptiMAL® at
this event.

 

Richard Buick, CSO of Fusion, said: "I am really pleased that the U.S. Patent
Office has granted the OptiMAL® Library patent application. This confirms our
unique approach to antibody library design and protects Fusion's OptiMAL®
antibody library for years to come."

 

Adrian Kinkaid, CEO of Fusion, said: "This good news arrives at an almost
perfect point in time as we confirm the desired binding properties of
antibodies discovered using OptiMAL® and as we prepare for the formal
commercial launch of the service."

 

 

Enquiries:

 

 Fusion Antibodies plc                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                         Tel: +44 (0)20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                      Tel: +44 (0)207 186 9952

 Walbrook PR                                                     Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001

 

Investor
Hub
 
 

We encourage all investors to share questions on this announcement via our
investor hub https://investorhub.fusionantibodies.com/link/rJaa9e
(https://investorhub.fusionantibodies.com/link/rJaa9e)

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and/or expressed over 750 antibodies and successfully completed over 250
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEASPSELFSEEA